2024-05-03 05:20:32 ET
Summary
- Cardinal Health reported Q3 earnings that beat EPS consensus and increased their FY24 guidance, particularly in the pharmaceutical segment.
- The loss of the OptumRx contract is seen as a short-term blip with minimal long-term impact on the investment thesis.
- The specialty business of Cardinal Health shows potential for growth even beyond current guidance.
- DCF analysis suggests a price target of $128.
I am updating my previous analysis on Cardinal Health (CAH) in light of Q3 2024 earnings, which were released pre-market on Thursday, May 2nd....
Read the full article on Seeking Alpha
For further details see:
Cardinal Health Q3 Earnings: Undervalued On Strong Guidance